Sinobioway Medicine(SZ:002581) Zheng Quan Zhi Xing·2025-08-19 11:09Core Viewpoint - The legal opinion letter from Zhejiang Tiance (Shenzhen) Law Firm confirms that Shandong Weiming Bio-Pharmaceutical Co., Ltd. has complied with relevant laws and regulations regarding the cancellation of certain stock options under its 2023 stock option incentive plan [1][9]. Group 1: Implementation of the Incentive Plan - The company has implemented the 2023 stock option incentive plan and has obtained necessary approvals from the board and independent directors [3][4]. - The supervisory board has verified that the individuals included in the incentive plan meet the qualifications as per the Company Law and relevant regulations [6][7]. Group 2: Approval and Authorization for Cancellation - The company has conducted necessary meetings to approve the cancellation of stock options that were not exercised during the first exercise period [7][8]. - The first exercise period for the stock options is set from May 30, 2024, to May 29, 2025, with a total of 16,617,396 stock options remaining unexercised by the end of this period [8][9]. Group 3: Compliance with Regulations - The cancellation of stock options is in accordance with the provisions of the Management Measures and the draft incentive plan [8][9]. - The company is required to fulfill its information disclosure obligations and complete related procedures following the cancellation [9].